$NTHISep 29, 2026, 8:52 AM ETAI processed
NTHI completed $15M registered direct at $4.20 with $4.20-strike warrants
AI Summary
NeOnc completed a $15.0 million registered direct offering in September at $4.20 per share, issuing roughly 3.57M shares and attached warrants with a $4.20 exercise price; proceeds were earmarked for working capital, general corporate purposes and redemption of Series A convertible preferred stock. The company also redeemed all 6,000 outstanding Series A preferred shares for $6.0M (removing that potential convertible dilution) and has a Type B FDA meeting for NEO212 scheduled for November 17, 2026 as the next clinical catalyst. Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.
Positives
- Raised $15.0M of gross proceeds in the completed registered direct
- Redeemed all 6,000 Series A preferred shares for $6.0M, eliminating that convertible dilution
- Proceeds designated for working capital/general purposes which can fund near-term operations
Negatives
- Immediate dilution from the completed registered direct (≈3.57M new common shares)
- Warrants issued at $4.20 strike add potential future dilution if exercised
- Warrant count, expiration and exercise timing not disclosed in the article
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: date unknown
Dilution status
delayed
Dilution timing
Dilution status: Delayed